Transcept Pharmaceuticals, Inc. (TSPT) Reports Q3 Loss of $0.37, Sales Top Expectations
Tweet
Share
E-mailGet Alerts TSPT Hot Sheet
Join SI Premium – FREE
Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT) reported Q3 EPS of ($0.37), $0.04 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $625 thousand versus the consensus estimate of $520 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
- Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c
- Applied Materials (AMAT) Tops Q3 EPS by 10c, Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
